EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beyond endocrine resistance: estrogen receptor (ESR1) activating mutations mediate chemotherapy resistance through the JNK/c-Jun MDR1 pathway in breast cancer

Marwa Taya, Keren Merenbakh-Lamin, Asia Zubkov, Zohar Honig, Alina Kurolap, Ori Mayer, Noam Shomron, Ido Wolf, Tami Rubinek

Breast Cancer Research and Treatment · 2025

DOI: 10.1007/s10549-024-07507-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2025. Verfasst von Marwa Taya und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Tel Aviv Sourasky Medical Center, 6 Weizmann St., 6423906, Tel Aviv, Israel. marwa.taya@gmail.com. Hauptthemen laut MEDLINE: Estrogen Receptor alpha, Breast Neoplasms, Drug Resistance, Neoplasm, Mutation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tel Aviv University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

All patients with metastatic breast cancer (MBC) expressing estrogen receptor-α (ESR1) will eventually develop resistance to endocrine therapies. In up to 40% of patients, this resistance is caused by activating mutations in the ligand-binding domain (LBD) of ESR1. Accumulating clinical evidence indicate adverse outcomes for these patients, beyond that expected by resistance to endocrine therapy. Here we aimed to study the role of ESR1 mutations in conferring chemoresistance in BC cells.

Methods

MCF-7 cells harboring Y537S and D538G ESR1 mutations (mut-ER) were employed to study the response to chemotherapy drugs, paclitaxel and doxorubicin, using viability and apoptotic assay in vitro, and tumor growth in vivo. JNK/c-Jun/MDR1 pathway was studied using qRT-PCR, western-blot, gene-reporter and ChIP assays. MDR1 expression was analyzed in clinical samples using IHC.

Results

Cell harboring ESR1 mutations displayed relative chemoresistance compared to WT-ER, evidenced by higher viability and reduced apoptosis as well as resistance to paclitaxel in vivo. To elucidate the underlying mechanism, MDR1 expression was examined and elevated levels were observed in mut-ER cells, and in clinical BC samples. MDR1 is regulated by the c-Jun pathway, and we showed high correlation between these two genes in BC using TCGA databases. Accordingly, we detected higher JNK/c-Jun expression and activity in ESR1-mutated cells, as well as increased occupancy of c-Jun in MDR1 promoter. Importantly, JNK inhibition decreased MDR1 expression and restored sensitivity to chemotherapy.

Conclusions

Taken together, these data indicate that ESR1 mutations confer chemoresistance through activation of the JNK/MDR1 axis. These finding suggest a novel treatment option for BC tumors expressing ESR1 mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Estrogen Receptor alphaBreast NeoplasmsDrug Resistance, NeoplasmMutationProto-Oncogene Proteins c-junHumansFemaleAnimalsMiceATP Binding Cassette Transporter, Subfamily BMCF-7 CellsXenograft Model Antitumor AssaysApoptosisGene Expression Regulation, NeoplasticMAP Kinase Signaling SystemPaclitaxelDoxorubicinSignal Transduction

Stichwörter der Autor:innen

Activating mutationsChemoresistanceJNK inhibitorJNK/c-Jun signaling pathwayMDR1

Substanzen

Estrogen Receptor alphaESR1 protein, humanProto-Oncogene Proteins c-junABCB1 protein, humanATP Binding Cassette Transporter, Subfamily BPaclitaxelDoxorubicin

Autor:innen und Institutionen

  • Department of Oncology, Tel Aviv Sourasky Medical Center, 6 Weizmann St., 6423906, Tel Aviv, Israel. marwa.taya@gmail.com.
  • The Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel. marwa.taya@gmail.com.
  • Department of Oncology, Tel Aviv Sourasky Medical Center, 6 Weizmann St., 6423906, Tel Aviv, Israel.
  • Institute of Pathology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • The Genetics Institute and Genomics Center, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • The Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.

Förderung

  • Tel Aviv University

Zitieren

APA

Taya, M., Merenbakh-Lamin, K., Zubkov, A., Honig, Z., Kurolap, A., Mayer, O., Shomron, N., Wolf, I., & Rubinek, T. (2025). Beyond endocrine resistance: estrogen receptor (ESR1) activating mutations mediate chemotherapy resistance through the JNK/c-Jun MDR1 pathway in breast cancer. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07507-3

Vancouver

Taya M, Merenbakh-Lamin K, Zubkov A, Honig Z, Kurolap A, Mayer O, et al. Beyond endocrine resistance: estrogen receptor (ESR1) activating mutations mediate chemotherapy resistance through the JNK/c-Jun MDR1 pathway in breast cancer. Breast Cancer Research and Treatment. 2025. doi:10.1007/s10549-024-07507-3

BibTeX
@article{Taya2025,
  author = {Taya, Marwa and Merenbakh-Lamin, Keren and Zubkov, Asia and Honig, Zohar and Kurolap, Alina and Mayer, Ori and Shomron, Noam and Wolf, Ido and Rubinek, Tami},
  title = {Beyond endocrine resistance: estrogen receptor (ESR1) activating mutations mediate chemotherapy resistance through the JNK/c-Jun MDR1 pathway in breast cancer},
  journal = {Breast Cancer Research and Treatment},
  year = {2025},
  doi = {10.1007/s10549-024-07507-3}
}
Kostenlos starten →